深圳新星(603978.SH):擬投資7億元建年產15000噸的六氟磷酸鋰項目
格隆匯11月5日丨深圳新星(603978.SH)公佈,因戰略發展需要,公司全資子公司松巖冶金材料(全南)有限公司(“松巖冶金”)擬投資人民幣7億元在江西省贛州市全南縣松巖工業園內利用現有廠房建設年產15000噸的六氟磷酸鋰項目。
項目建設期為1.5年,計劃分四期建設:第一期年產能800噸,目前已經完成示範生產線的建設,各項調試已經基本完畢,生產用原材料、人員、配套設施均已到位,截止當前設備試車工作順利;第二期年產能3000噸,目前設備已採購完畢,預計2021年12月進廠安裝;第三期年產能5000噸,2021年11月底啟動設備採購;第四期年產能 6000噸,2022年啟動設備採購與安裝。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.